Remove 2050 Remove Cannabinoids Remove Programs Remove Safety
article thumbnail

Policy Analysis Paper: Medicinal cannabis and driving: the intersection of health and road safety policy

Cannabis Law Report

Road safety risks associated with medicinal cannabis appear similar or lower than numerous other potentially impairing prescription medications. The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia. Available online 6 June 2021.

Policy 66
article thumbnail

Australia – Policy Analysis: Medicinal cannabis and driving: the intersection of health and road safety policy – “there is little evidence to justify the differential treatment of medicinal cannabis patients, compared with those taking other prescription medications”

Cannabis Law Report

The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia. Behaviours and Health Risks Program, Burnet Institute, Melbourne, VIC 3004, Australia. Road safety. Office of Medicinal Cannabis, Department of Health, Melbourne, VIC 3000, Australia.

article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

It is worth noting that Marinol ® (dronabinol) is an FDA-approved synthetic cannabinoid that was placed in Schedule III under the CSA in 1999.). 2050 , 2051, 2075; Pub. Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and. .

Banking 45